Alkem Laboratories News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Alkem Laboratories Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Alkem Laboratories Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news and updates on Alkem Laboratories from all sources in a single place.

Alkem Laboratories Ltd.

25 Nov 2025

5609.50

-1.33%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Schedule of Analyst / Investor Meet - Intimation

pdf

Alkem Laboratories Ltd.

22 Nov 2025

5609.50

-1.33%

Company Update

Alkem Laboratories Ltd - 539523 - GMP Inspection By Ministry Of Health, Armenia At The Company''s …

BSE India

Closure of GMP Inspection by Ministry of Health, Armenia at the Company''s manufacturing facility located at Sikkim, India.

pdf

Alkem Laboratories Ltd.

20 Nov 2025

5609.50

-1.33%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release - ALkem launches probiotic "DSS", the original De Simone formulation, in India for gut health management

pdf

Alkem Laboratories Ltd.

19 Nov 2025

5609.50

-1.33%

Earnings Call

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Q2 & H1 FY26 - Earnings Conference Call Transcript

pdf

Alkem Laboratories Ltd.

18 Nov 2025

5609.50

-1.33%

Company Update

Alkem Laboratories Ltd - 539523 - Disclosure Under Regulation 30 Of SEBI LODR.

BSE India

Pursuant to Regulation 30 of SEBI LODR Regulation,2025 this is to inform you that the Company has received an order passed by the statutory authority under the Goods and Services Tax Act,2017. The relevant disclosure is enclosed herewith.

pdf

Alkem Laboratories Ltd.

14 Nov 2025

5609.50

-1.33%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Advertisement- Disclosure under Regulation 30

pdf

Alkem Laboratories Ltd.

14 Nov 2025

5609.50

-1.33%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Please find enclosed herewith the details of the Analyst / Institutional Investor meetings.

pdf

Alkem Laboratories Ltd.

14 Nov 2025

5609.50

-1.33%

Traction across segments scaling margins to newer highs

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories (Alkem) delivered a strong Q2FY26 result led by traction across regions. Growth in India biz (+12% YoY) was led by better traction in chronic therapies and recent foray in medical devices segment, while new launches including gEntresto boosted US revenue (+28%).

Number of FII/FPI investors increased from 551 to 589 in Sep 2025 qtr.

Alkem Laboratories Ltd.

13 Nov 2025

5609.50

-1.33%

Alkem Labs Q2 profit rises 11% on strong India, international sales

Business Standard

India sales grew 14% Y-o-Y to 2,766 crore in the September quarter, while international sales rose 29.5% to 1,189 crore, contributing 31.7% to overall revenue

Number of FII/FPI investors increased from 551 to 589 in Sep 2025 qtr.

Alkem Laboratories Ltd.

13 Nov 2025

5609.50

-1.33%

Alkem Laboratories Results Earnings Call for Q2FY26

Conference Call with Alkem Laboratories Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Management in attendance

audio

Is Alkem Laboratories Ltd. worth buying?

140 Votes:

Buy 79.29%

Sell 14.29%

Hold 6.43%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Neutral SEE REPORTS >

pdf